|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Kinetic analysis, structural studies and prediction of pKa values of Bacillus KR-8104 a-amylase: The determinants of pH-activity profile 显示文摘 | ALIKHAJEH J KHAJEH K MANESH M N RANJBAR B SAJEDI R H NADERI-MANESH H | 2007 | Enzyme Microbiology Technology2007，41，2： | 1 |
| 2 | Agrobacterium mediated genetic transformation in Hevea brasiliensis for recombinant protein production显示文摘 | Kala R G Anu K S Manesh K | 2006 | Journal of plantation crops2006，34，3： | 1 |
| 3 | Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation 显示文摘 | Manesh R Kenneth W Jyotsna Garg | 2011 | N Engl J Med2011，365，10： | 1 |
| 4 | Rivaroxaban versus warfarin in nonvalvular atrial fibrillation 显示文摘 | Manesh R Patel MD Kenneth W | 2011 | N Engl J Med2011，365，10： | 1 |
| 5 | Intra - aortic ballon pump effects on macrocirculation and microcirculation in cardiogenic shock patiens supported by venoarterial extracorporeal membrane oxygenat 显示文摘 | Manesh R Richard W Huiman X | 2011 | JAMA2011，306，12： | 1 |
| 6 | ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness criteria for coronary revascularization A report of the american college of cardiology foundation appropriateness criteria task force,society for cardiovascular angiography and Interventions,society of thoracic surgeons,american association for thoracic surgery,american heart association,and the american society of nuclear cardiology显示文摘 | Manesh R | 2009 | Circulation2009，119，： | 1 |
| 7 | Rivarox- aban versus Warfarin in Nonvalvular Atrial Fibrilla- tion显示文摘 | Manesh R Kenneth W Jyotsna Garg | 2011 | N Engl J Med2011，365，10： | 1 |
| 8 | Myelin in- hibits oligodendroglial maturation and regulates oligoden- droeytic transcription factor expression 显示文摘 | Plemel J R Manesh S B Sparling J S | 2013 | Glia2013，61，9： | 1 |
| 9 | Optimum water content and maximum dry unit weight of clayey gravels at different compactive efforts显示文摘 | JESMANI M MANESH A N HOSEINI S M R | 2008 | Electronic Journal of Geotechnical Engineering2008，13，： | 1 |
| 10 | Confinement effects on high - strength concrete 显示文摘 | MEI H KIIOUSIS P D EHSANi M R SAADAT- MANESH H | 2001 | ACI Structural Journal2001，98，4： | 1 |
| 11 | Low diagnostic yield of elective coronary angiography显示文摘 | Manesh R Patel MD Eric D | 2010 | N Engl J Med2010，362，10： | 1 |
| 12 | Impact of frailty on endoscopic retrograde cholangiopancreatography outcomes in nonagenarians:A United States national experience显示文摘BACKGROUND Endoscopic retrograde cholangiopancreatography(ERCP)is an essential therapeutic tool for biliary and pancreatic diseases.Frail and elderly patients,especially those aged≥90 years are generally considered a higher-risk population for ERCP-related complications.AIM To investigate outcomes of ERCP in the Non-agenarian population(≥90 years)concerning Frailty.METHODS This is a cohort study using the 2018-2020 National Readmission Database.Patients aged≥90 were identified who underwent ERCP,using the international classification of diseases-10 code with clinical modification.Johns Hopkins’s adjusted clinical groups frailty indicator was used to classify patients as frail and non-frail.The primary outcome was mortality,and the secondary outcomes were morbidity and the 30 d readmission rate related to ERCP.We used univariate and multivariate regression models for analysis.RESULTS A total of 9448 patients were admitted for any indications of ERCP.Frail and non-frail patients were 3445(36.46%)and 6003(63.53%)respectively.Indications for ERCP were Choledocholithiasis(74.84%),Biliary pancreatitis(9.19%),Pancreatico-biliary cancer(7.6%),Biliary stricture(4.84%),and Cholangitis(1.51%).Mortality rates were higher in frail group[adjusted odds ratio(aOR)=1.68,P=0.02].The Intra-procedural complications were insigni-ficant between the two groups which included bleeding(aOR=0.72,P=0.67),accidental punctures/lacerations(aOR=0.77,P=0.5),and mechanical ventilation rates(aOR=1.19,P=0.6).Post-ERCP complication rate was similar for bleeding(aOR=0.72,P=0.41)and post-ERCP pancreatitis(aOR=1.4,P=0.44).Frail patients had a longer length of stay(6.7 d vs 5.5 d)and higher mean total charges of hospitalization($78807 vs$71392)compared to controls(P<0.001).The 30 d all-cause readmission rates between frail and non-frail patients were similar(P=0.96).CONCLUSION There was a significantly higher mortality risk and healthcare burden amongst nonagenarian frail patients undergoing ERCP compared to non-frail.Larger studies are warranted to investigate and mitigate modifiable risk factors. | Sanket Dhirubhai Basida Dushyant Singh Dahiya Muhammad Nadeem Yousaf Brinda Basida Bhanu Siva Mohan Pinnam Manesh Kumar Gangwani Hassam Ali Sahib Singh Yash R Shah Daksh Ahluwalia Mihir Prakash Shah Saurabh Chandan Neil R Sharma Shyam Thakkar | 2024 | World Journal of Gastrointestinal Endoscopy2024，16，3： | 0 |
| 13 | Acute pancreatitis in liver transplant hospitalizations:Identifying national trends,clinical outcomes and healthcare burden in the United States显示文摘BACKGROUND Acute pancreatitis(AP)in liver transplant(LT)recipients may lead to poor clinical outcomes and development of severe complications.AIM We aimed to assess national trends,clinical outcomes,and the healthcare burden of LT hospitalizations with AP in the United States(US).METHODS The National Inpatient Sample was utilized to identify all adult(≥18 years old)LT hospitalizations with AP in the US from 2007–2019.Non-LT AP hospitalizations served as controls for comparative analysis.National trends of hospitalization characteristics,clinical outcomes,complications,and healthcare burden for LT hospitalizations with AP were highlighted.Hospitalization characteristics,clinical outcomes,complications,and healthcare burden were also compared between the LT and non-LT cohorts.Furthermore,predictors of inpatient mortality for LT hospitalizations with AP were identified.All P values≤0.05 were considered statistically significant.RESULTS The total number of LT hospitalizations with AP increased from 305 in 2007 to 610 in 2019.There was a rising trend of Hispanic(16.5%in 2007 to 21.1%in 2018,P-trend=0.0009)and Asian(4.3%in 2007 to 7.4%in 2019,p-trend=0.0002)LT hospitalizations with AP,while a decline was noted for Blacks(11%in 2007 to 8.3%in 2019,P-trend=0.0004).Furthermore,LT hospitalizations with AP had an increasing comorbidity burden as the Charlson Comorbidity Index(CCI)score≥3 increased from 41.64%in 2007 to 62.30%in 2019(P-trend<0.0001).We did not find statistically significant trends in inpatient mortality,mean length of stay(LOS),and mean total healthcare charge(THC)for LT hospitalizations with AP despite rising trends of complications such as sepsis,acute kidney failure(AKF),acute respiratory failure(ARF),abdominal abscesses,portal vein thrombosis(PVT),and venous thromboembolism(VTE).Between 2007–2019,6863 LT hospitalizations with AP were compared to 5649980 non-LT AP hospitalizations.LT hospitalizations with AP were slightly older(53.5 vs 52.6 years,P=0.017)and had a higher proportion of patients with CCI≥3(51.5%vs 19.8%,P<0.0001)compared to the non-LT cohort.Additionally,LT hospitalizations with AP had a higher proportion of Whites(67.9%vs 64.6%,P<0.0001)and Asians(4%vs 2.3%,P<0.0001),while the non-LT cohort had a higher proportion of Blacks and Hispanics.Interestingly,LT hospitalizations with AP had lower inpatient mortality(1.37%vs 2.16%,P=0.0479)compared to the non-LT cohort despite having a higher mean age,CCI scores,and complications such as AKF,PVT,VTE,and the need for blood transfusion.However,LT hospitalizations with AP had a higher mean THC($59596 vs$50466,P=0.0429)than the non-LT cohort.CONCLUSION In the US,LT hospitalizations with AP were on the rise,particularly for Hispanics and Asians.However,LT hospitalizations with AP had lower inpatient mortality compared to non-LT AP hospitalizations. | Dushyant Singh Dahiya Vinay Jahagirdar Saurabh Chandan Manesh Kumar Gangwani Nooraldin Merza Hassam Ali Smit Deliwala Muhammad Aziz Daryl Ramai Bhanu Siva Mohan Pinnam Jay Bapaye Chin-I Cheng Sumant Inamdar Neil R Sharma Mohammad Al-Haddad | 2023 | World Journal of Hepatology2023，15，6： | 0 |
| 14 | Peptic ulcer disease in non-alcoholic fatty liver disease hospitalizations:A new challenge on the horizon in the United States显示文摘BACKGROUND Peptic ulcer disease(PUD)is frequently seen in patients with liver cirrhosis.However,current literature lacks data on PUD in non-alcoholic fatty liver disease(NAFLD)hospitalizations.AIM To identify trends and clinical outcomes of PUD in NAFLD hospitalizations in the United States.METHODS The National Inpatient Sample was utilized to identify all adult(≥18 years old)NAFLD hospitalizations with PUD in the United States from 2009-2019.Hospitalization trends and outcomes were highlighted.Furthermore,a control group of adult PUD hospitalizations without NAFLD was also identified for a comparative analysis to assess the influence of NAFLD on PUD.RESULTS The total number of NAFLD hospitalizations with PUD increased from 3745 in 2009 to 3805 in 2019.We noted an increase in the mean age for the study population from 56 years in 2009 to 63 years in 2019(P<0.001).Racial differences were also prevalent as NAFLD hospitalizations with PUD increased for Whites and Hispanics,while a decline was observed for Blacks and Asians.The all-cause inpatient mortality for NAFLD hospitalizations with PUD increased from 2%in 2009 to 5%in 2019(P<0.001).However,rates of Helicobacter pylori(H.pylori)infection and upper endoscopy decreased from 5%in 2009 to 1%in 2019(P<0.001)and from 60%in 2009 to 19%in 2019(P<0.001),respectively.Interestingly,despite a significantly higher comorbidity burden,we observed lower inpatient mortality(2%vs 3%,P=0.0004),mean length of stay(LOS)(11.6 vs 12.1 d,P<0.001),and mean total healthcare cost(THC)($178598 vs$184727,P<0.001)for NAFLD hospitalizations with PUD compared to non-NAFLD PUD hospitalizations.Perforation of the gastrointestinal tract,coagulopathy,alcohol abuse,malnutrition,and fluid and electrolyte disorders were identified to be independent predictors of inpatient mortality for NAFLD hospitalizations with PUD.CONCLUSION Inpatient mortality for NAFLD hospitalizations with PUD increased for the study period.However,there was a significant decline in the rates of H.pylori infection and upper endoscopy for NAFLD hospitalizations with PUD.After a comparative analysis,NAFLD hospitalizations with PUD had lower inpatient mortality,mean LOS,and mean THC compared to the non-NAFLD cohort. | Dushyant Singh Dahiya Vinay Jahagirdar Hassam Ali Manesh Kumar Gangwani Muhammad Aziz Saurabh Chandan Amandeep Singh Abhilash Perisetti Aakriti Soni Sumant Inamdar Madhusudhan R Sanaka Mohammad Al-Haddad | 2023 | World Journal of Hepatology2023，15，4： | 0 |
| 15 | Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions显示文摘Fecal microbiota transplantation(FMT)offers a potential treatment avenue for hepatic encephalopathy(HE)by leveraging beneficial bacterial displacement to restore a balanced gut microbiome.The prevalence of HE varies with liver disease severity and comorbidities.HE pathogenesis involves ammonia toxicity,gut-brain communication disruption,and inflammation.FMT aims to restore gut microbiota balance,addressing these factors.FMT's efficacy has been explored in various conditions,including HE.Studies suggest that FMT can modulate gut microbiota,reduce ammonia levels,and alleviate inflammation.FMT has shown promise in alcohol-associated,hepatitis B and C-associated,and non-alcoholic fatty liver disease.Benefits include improved liver function,cognitive function,and the slowing of disease progression.However,larger,controlled studies are needed to validate its effectiveness in these contexts.Studies have shown cognitive improvements through FMT,with potential benefits in cirrhotic patients.Notably,trials have demonstrated reduced serious adverse events and cognitive enhancements in FMT arms compared to the standard of care.Although evidence is promising,challenges remain:Limited patient numbers,varied dosages,administration routes,and donor profiles.Further large-scale,controlled trials are essential to establish standardized guidelines and ensure FMT's clinical applications and efficacy.While FMT holds potential for HE management,ongoing research is needed to address these challenges,optimize protocols,and expand its availability as a therapeutic option for diverse hepatic conditions. | Yash R Shah Hassam Ali Angad Tiwari David Guevara-Lazo Natalia Nombera-Aznaran Bhanu Siva Mohan Pinnam Manesh Kumar Gangwani Harishankar Gopakumar Amir H Sohail SriLakshmiDevi Kanumilli Ernesto Calderon-Martinez Geetha Krishnamoorthy Nimish Thakral Dushyant Singh Dahiya | 2024 | World Journal of Hepatology2024，16，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员